ABMT: AI 评分 68/100 — AI 分析 (4月 2026)

Advanced Biomedical Technologies, Inc. is a development stage company focused on designing, developing, manufacturing, and marketing biomaterial internal fixation devices. Their products target orthopedic trauma, sports-related injuries, cartilage repair, reconstructive dental procedures, and related treatments.

Key Facts: AI Score: 68/100 Sector: Healthcare

公司概况

概要：

Advanced Biomedical Technologies, Inc. is a development stage company specializing in biomaterial internal fixation devices, including surgical screws and binding wires, targeting orthopedic trauma and reconstructive dental procedures. With a negative P/E ratio and high gross margin, ABMT operates in the competitive medical device sector, facing challenges in achieving profitability and scaling production.

ABMT是做什么的？

Founded in 2002 and rebranded in 2009 from Geostar Mineral Corporation, Advanced Biomedical Technologies, Inc. (ABMT) is a development stage company focused on the design, development, manufacturing, and marketing of biomaterial internal fixation devices. The company's core offerings include polymer osteosynthesis devices such as surgical screws, binding wires, and rods, along with related medical devices. These products are intended for use in the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, reconstructive dental procedures, and related treatments. Based in New York City, ABMT aims to provide innovative solutions in the medical device field, particularly in the area of internal fixation. As a development stage company, ABMT is likely focused on research and development, clinical trials, and securing regulatory approvals for its products. The company's success will depend on its ability to effectively commercialize its products and gain market share in a competitive landscape. With a relatively small team of 17 employees, ABMT faces the challenges of scaling its operations and competing with larger, more established players in the medical device industry.

ABMT的投资论点是什么？

Advanced Biomedical Technologies, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on polymer osteosynthesis devices for orthopedic and dental applications addresses a significant market need. However, as a development stage company with a negative P/E ratio of -0.05 and a negative profit margin of -190.2%, ABMT's financial viability is a major concern. Key value drivers include successful product development, regulatory approvals, and market adoption of its devices. Growth catalysts include expanding its product line and entering new geographic markets. Potential risks include competition from established medical device companies, challenges in securing funding, and the uncertainty of regulatory approvals. Investors should carefully consider the company's financial position and the inherent risks associated with development stage companies before investing. The company's high Beta of 1.46 suggests higher volatility compared to the overall market.

ABMT在哪个行业运营？

Advanced Biomedical Technologies, Inc. operates in the medical device industry, a sector characterized by rapid innovation, stringent regulatory requirements, and intense competition. The market for internal fixation devices is driven by the increasing prevalence of orthopedic trauma, sports-related injuries, and the growing demand for reconstructive dental procedures. ABMT faces competition from established medical device companies with greater resources and broader product portfolios. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively commercialize its technologies in a dynamic and competitive market.

Medical - Devices

Healthcare

ABMT有哪些增长机遇？

Expansion into New Therapeutic Areas: ABMT can explore opportunities to expand its product offerings into adjacent therapeutic areas within orthopedics and reconstructive surgery. For example, the company could develop devices for spinal fusion or joint replacement. The global market for spinal implants is projected to reach $12.5 billion by 2028, presenting a significant growth opportunity for ABMT. Timeline: 2-3 years.
Geographic Expansion: ABMT can pursue geographic expansion into international markets, particularly in emerging economies where there is a growing demand for advanced medical devices. The Asia-Pacific region is expected to be the fastest-growing market for medical devices, driven by increasing healthcare spending and a growing aging population. Timeline: 3-5 years.
Strategic Partnerships: ABMT can form strategic partnerships with hospitals, clinics, and distributors to expand its market reach and accelerate product adoption. Collaborating with key opinion leaders and academic institutions can also help to validate the company's technology and enhance its credibility. Timeline: 1-2 years.
Product Innovation: ABMT can invest in research and development to develop innovative biomaterial internal fixation devices with improved performance, biocompatibility, and ease of use. The company can also explore the use of advanced manufacturing techniques, such as 3D printing, to create customized implants tailored to individual patient needs. Timeline: Ongoing.
Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe is crucial for ABMT to commercialize its products and gain market access. The company should prioritize regulatory compliance and invest in the necessary resources to navigate the regulatory approval process efficiently. Timeline: Ongoing.

Gross Margin of 81.9% indicates strong potential profitability if sales volume increases.
Negative P/E Ratio of -0.05 reflects the company's current lack of profitability.
Profit Margin of -190.2% highlights significant operational challenges and high expenses relative to revenue.
Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
Beta of 1.46 suggests the stock is more volatile than the market.

ABMT提供哪些产品和服务？

Designs biomaterial internal fixation devices.
Develops polymer osteosynthesis devices.
Manufactures surgical screws and binding wires.
Markets medical devices for orthopedic trauma.
Offers solutions for sports-related medical treatment.
Provides devices for cartilage repair.
Creates products for reconstructive dental procedures.

ABMT如何赚钱？

Develops and manufactures biomaterial-based medical devices.
Sells products directly to hospitals and clinics.
Distributes products through a network of distributors.
Generates revenue from the sale of surgical screws, binding wires, and related devices.

Hospitals and surgical centers.
Orthopedic surgeons.
Dental surgeons.
Sports medicine clinics.

Proprietary biomaterial formulations.
Specialized expertise in polymer osteosynthesis.
Focus on niche applications in orthopedic and dental surgery.
Established relationships with key opinion leaders in the medical field.

什么因素可能推动ABMT股价上涨？

Upcoming: Potential FDA approval for new biomaterial internal fixation devices.
Ongoing: Research and development efforts to expand product line.
Ongoing: Strategic partnerships with hospitals and clinics to increase market reach.

ABMT的主要风险是什么？

Potential: Competition from established medical device companies.
Potential: Challenges in securing funding for ongoing operations.
Potential: Uncertainty of regulatory approvals.
Ongoing: Negative profitability and cash flow.
Ongoing: Limited financial disclosure due to OTC listing.

ABMT的核心优势是什么？

Proprietary biomaterial technology.
Focus on a specific niche market.
Potential for high gross margins.
Experienced management team.

ABMT的劣势是什么？

Development stage company with limited revenue.
Negative profitability and cash flow.
Small size and limited resources.
Dependence on regulatory approvals.

ABMT有哪些机遇？

Expansion into new therapeutic areas.
Geographic expansion into emerging markets.
Strategic partnerships with hospitals and distributors.
Increasing demand for minimally invasive surgical procedures.

ABMT面临哪些威胁？

Competition from larger, more established medical device companies.
Technological obsolescence.
Changes in regulatory requirements.
Product liability claims.

ABMT的竞争对手是谁？

Asensus Surgical, Inc. — Focuses on surgical robotics. — (ASFX)
Ecg Imaging Inc — Provides medical imaging solutions. — (ECGI)
Faron Pharmaceuticals Oy — Develops novel drugs for immune and vascular diseases. — (FIORF)
HealthStream, Inc. — Provides workforce development solutions for healthcare organizations. — (HSMD)
Medexus Pharmaceuticals Inc — Focuses on commercializing innovative rare disease treatments. — (MDXL)

Key Metrics

MoonshotScore: 68/100

Company Profile

CEO: Hui Wang
Headquarters: New York City, US
Employees: 17
Founded: 2010

AI Insight

AI analysis pending for ABMT

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Advanced Biomedical Technologies, Inc. do?

Advanced Biomedical Technologies, Inc. is a development stage company that designs, develops, manufactures, and markets biomaterial internal fixation devices. These devices, including surgical screws, binding wires, and rods, are primarily used in orthopedic trauma, sports-related injuries, cartilage repair, and reconstructive dental procedures. The company focuses on polymer osteosynthesis devices and aims to provide innovative solutions in the medical device field. As a development stage company, ABMT is currently working to commercialize its products and gain market share.

What do analysts say about ABMT stock?

As of March 16, 2026, there is no readily available analyst coverage for Advanced Biomedical Technologies, Inc. due to its status as an OTC-listed, development stage company. Key valuation metrics such as P/E ratio (-0.05) and profit margin (-190.2%) indicate that the company is not currently profitable. Investors should carefully consider the risks and uncertainties associated with investing in micro-cap, OTC-listed companies before making any investment decisions. Further research and due diligence are recommended to assess the company's potential for future growth and profitability.

What are the main risks for ABMT?

Advanced Biomedical Technologies, Inc. faces several significant risks. As a development stage company, it has limited revenue and negative profitability, making it reliant on securing additional funding. Competition from larger, more established medical device companies poses a threat to its market share. The company's products are subject to regulatory approvals, which can be lengthy and uncertain. Furthermore, as an OTC-listed company, ABMT faces risks related to limited financial disclosure and lower liquidity, increasing the potential for price volatility and manipulation.